NCT01801319Unknown不适用
A Clinical Evaluation of Subcallosal Cingulate Gyrus Deep Brain Stimulation for Treatment-Resistant Depression
适应症
试验速览
- 阶段
- 不适用
- 入组人数
- 40
- 试验地点
- 2
- 主要终点
- Primary Efficacy: Changes in the Hamilton Depression Rating Scale-17
研究概览
简要总结
This is a randomized, placebo-controlled double-blind cross-over trial evaluating the safety, efficacy, daily functioning, and health-related quality of life of Subcallosal Cingulate Gyrus Deep Brain Stimulation (SCG DBS) for participants with Treatment-Resistant Depression (TRD). A total of 40 eligible participants will be randomized to four treatment sequences (10 participants per sequence). Each participant will be treated over a 6-month period with active or sham stimulation in which both the participants and the attending psychiatrists will be blinded to treatment allocation.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 21 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Men and women (non-pregnant) ages 21-70 years;
- •Diagnosed with non-psychotic major depressive disorder, single or recurrent episode by DSM-IV-TR criteria;
- •First episode onset before age 45;
- •Current episode > 12 months duration;
- •In the current episode: Documented resistance (i.e. persistence of the major depressive episode) to a minimum of 4 adequate depression treatments from at least 3 different treatment categories (e.g. SSRI's, SNRI's, TCA's, MAO-inhibitors, Mirtazipine, Nefazodone, Trazodone, Bupropion, lithium augmentation, thyroid augmentation, ECT); Adequacy of treatments as defined by a score of at least 3 according to the amended Antidepressant Treatment History Form (ATHF) criteria;
- •Hamilton Depression Rating Scale (HDRS) of > 20 at 3 separate baseline visits, rated by 2 separate psychiatrists, Baseline 2 and Baseline 3 HDRS scores cannot improve ≥ 25%;
排除标准
- •A diagnosis of a bipolar I or bipolar II disorder by DSM-IV-TR criteria;
- •Meets criteria for borderline or antisocial personality disorder in the last 12 months by DSM-IV-TR criteria, derived from the Cluster B Personality.
- •In the current depressive episode, has been diagnosed with General Anxiety Disorder (GAD) - as defined by the DSM-IV-TR, and GAD is the primary diagnosis;
- •Has an intracranial Central Nervous System (CNS) disease that impairs motor, sensory or cognitive function or that requires intermittent or chronic medication (e.g., Parkinson's Disease, migraine, stroke, Huntington's, head trauma, etc.) with exception to non-migraine headaches;
- •Has been diagnosed with fibromyalgia or has a current condition which requires chronic pain narcotic usage (e.g. morphine, methadone);
- •Has been currently diagnosed with chronic fatigue syndrome;
- •Substantial suicidal risk as defined by (1) a current plan and intent, (2) clinician judgment that there is a clear immediate intent for self-harm, (3) more than 3 suicide attempts within the last 12 months;
- •Co-morbid obsessive compulsive disorder, post-traumatic stress disorder, panic disorder, bulimia or anorexia nervosa if previously present, must be in remission for 6 months as defined by DSM-IV-TR criteria, derived from the MINI;
- •Alcohol, medication, or illegal substance dependence within last 12 months;
- •Advanced cardiovascular disease which renders anesthesia and surgery as unsafe as determined by neurosurgeon;
- •Plans to use diathermy;
- •Have any metallic implants in the brain such as aneurysm clips or cochlear implants;
- •Currently participating in another investigational device, drug or surgical trial.
结局指标
主要结局
Primary Efficacy: Changes in the Hamilton Depression Rating Scale-17
时间窗: 3 and 6 months
evaluate change in HAMD-17 3 months and 6 months after implantation
次要结局
- The incidence of all adverse events(6 months)
- Showing SCG-DBS significantly increases health related quality of life compared to sham stimulation in patients with TRD(6 months)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
1 期
Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Effects of AMG 811 in Subjects With PsoriasisPsoriasisNCT01510951Amgen9
招募中
不适用
Treatment ResistAnt Depression Subcallosal CingulatE Network DBS (TRANSCEND)Treatment Resistant DepressionNCT06423430Abbott Medical Devices100
已完成
不适用
Subchondroplasty® Knee RCTBone Marrow EdemaKnee Pain ChronicOsteoarthritisKnee OsteoarthritisOsteoarthritis, KneeNCT03112200Zimmer Biomet131
已完成
不适用
Study of Glutathione, Vitamin C and Cysteine in Children With Autism and Severe Behavior ProblemsSevere Behavior DisorderAutismNCT00889538University of Louisville24
已完成
2 期
Efficacy of Circadin® 2 mg in Patients With Mild to Moderate Alzheimer Disease Treated With AChE InhibitorSleep DisorderAlzheimer's DiseaseNCT00940589Neurim Pharmaceuticals Ltd.73